Logo image of COCH

ENVOY MEDICAL INC (COCH) Stock Fundamental Analysis

NASDAQ:COCH - Nasdaq - US29415V1098 - Common Stock - Currency: USD

1.55  +0.11 (+7.64%)

Fundamental Rating

0

Taking everything into account, COCH scores 0 out of 10 in our fundamental rating. COCH was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of COCH have multiple concerns. COCH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COCH had negative earnings in the past year.
In the past year COCH has reported a negative cash flow from operations.
In the past 5 years COCH reported 4 times negative net income.
In the past 5 years COCH always reported negative operating cash flow.
COCH Yearly Net Income VS EBIT VS OCF VS FCFCOCH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

COCH has a worse Return On Assets (-255.89%) than 95.19% of its industry peers.
Industry RankSector Rank
ROA -255.89%
ROE N/A
ROIC N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COCH Yearly ROA, ROE, ROICCOCH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

COCH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCH Yearly Profit, Operating, Gross MarginsCOCH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

COCH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COCH has been increased compared to 1 year ago.
The debt/assets ratio for COCH is higher compared to a year ago.
COCH Yearly Shares OutstandingCOCH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
COCH Yearly Total Debt VS Total AssetsCOCH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -44.73, we must say that COCH is in the distress zone and has some risk of bankruptcy.
COCH has a Altman-Z score of -44.73. This is amonst the worse of the industry: COCH underperforms 94.65% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -44.73
ROIC/WACCN/A
WACC7.15%
COCH Yearly LT Debt VS Equity VS FCFCOCH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 1.09 indicates that COCH should not have too much problems paying its short term obligations.
COCH has a Current ratio of 1.09. This is amonst the worse of the industry: COCH underperforms 87.70% of its industry peers.
A Quick Ratio of 0.88 indicates that COCH may have some problems paying its short term obligations.
COCH's Quick ratio of 0.88 is on the low side compared to the rest of the industry. COCH is outperformed by 82.89% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 0.88
COCH Yearly Current Assets VS Current LiabilitesCOCH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

COCH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -143.90%.
Looking at the last year, COCH shows a decrease in Revenue. The Revenue has decreased by -9.40% in the last year.
EPS 1Y (TTM)-143.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.38%
Revenue 1Y (TTM)-9.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.03%

3.2 Future

The Earnings Per Share is expected to grow by 0.91% on average over the next years.
The Revenue is expected to decrease by -0.60% on average over the next years.
EPS Next Y8.54%
EPS Next 2Y0.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-16.05%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

COCH Yearly Revenue VS EstimatesCOCH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 100K 200K 300K
COCH Yearly EPS VS EstimatesCOCH Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COCH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCH Price Earnings VS Forward Price EarningsCOCH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCH Per share dataCOCH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COCH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVOY MEDICAL INC

NASDAQ:COCH (7/11/2025, 8:01:22 PM)

1.55

+0.11 (+7.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)N/A N/A
Inst Owners8.92%
Inst Owner Change0%
Ins Owners49.94%
Ins Owner Change1.84%
Market Cap33.06M
Analysts82
Price Target7.27 (369.03%)
Short Float %1.04%
Short Ratio4.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.12
Dividend Growth(5Y)N/A
DP-13.77%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.55%
Min EPS beat(2)-39.48%
Max EPS beat(2)16.38%
EPS beat(4)1
Avg EPS beat(4)-15.16%
Min EPS beat(4)-39.48%
Max EPS beat(4)16.38%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-41.47%
Min Revenue beat(2)-50.59%
Max Revenue beat(2)-32.36%
Revenue beat(4)0
Avg Revenue beat(4)-34.06%
Min Revenue beat(4)-50.59%
Max Revenue beat(4)-19.19%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.46%
EPS NY rev (1m)0.26%
EPS NY rev (3m)-4.66%
Revenue NQ rev (1m)-4.87%
Revenue NQ rev (3m)-25.71%
Revenue NY rev (1m)-1.96%
Revenue NY rev (3m)-29.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 155.95
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0.01
BVpS-1.14
TBVpS-1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -255.89%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-205.35%
ROA(5y)-123.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 493%
Cap/Sales 465.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 0.88
Altman-Z -44.73
F-Score1
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-143.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.38%
EPS Next Y8.54%
EPS Next 2Y0.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.4%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-22.03%
Revenue Next Year-16.05%
Revenue Next 2Y-0.6%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-313.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-288.87%
OCF growth 3YN/A
OCF growth 5YN/A